Analyst Price Targets — VOR
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 23, 2025 11:59 am | — | Robert W. Baird | $46.00 | $13.71 | TheFly | Vor Bio price target lowered to $46 from $64 at Baird |
| October 29, 2025 12:23 pm | — | H.C. Wainwright | $55.00 | $26.93 | TheFly | Vor Bio price target adjusted to $55 at H.C. Wainwright after reverse split |
| October 14, 2025 9:10 pm | — | Robert W. Baird | $64.00 | $30.81 | TheFly | Vor Bio upgraded to Outperform from Neutral at Baird |
| September 24, 2025 12:56 am | Stephen Willey | Stifel Nicolaus | $55.00 | $31.28 | TheFly | Vor Bio upgraded to Buy from Hold at Stifel |
| June 30, 2025 10:07 am | — | H.C. Wainwright | $3.00 | $1.62 | TheFly | Vor Bio upgraded to Buy from Neutral at H.C. Wainwright |
| April 27, 2022 6:14 am | — | Goldman Sachs | $6.00 | $5.60 | Benzinga | Goldman Sachs Initiates Coverage On Vor Biopharma with Neutral Rating, Announces Price Target of $6 |
Latest News for VOR
Vor Biopharma Inc. (VOR) Presents at TD Cowen 46th Annual Health Care Conference Transcript
BOSTON, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 46th Annual TD Cowen Health Care Conference in Boston, MA. Presentation: Monday, March 2, 2026 at 9:50am – 10:20 am ETLocation: Regis A live webcast and archived replay of the…
Vor Biopharma Inc. (NASDAQ: VOR - Get Free Report) has received an average recommendation of "Moderate Buy" from the fourteen brokerages that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation, seven have given a buy recommendation and one has assigned a strong
BOSTON, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced that it will be presenting and hosting 1x1 investor meetings at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company's recently announced…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for VOR.
U.S. House Trading
No House trades found for VOR.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.